The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Some good articles today. Eli Lily are ahead in the trials phase at present but mid/long term Tiziana have a real advantage with their non-intravenous approach.
There are obvious benefits of being ‘first to market’ and I think the timescales will probably work against Tiziana in this sense.
‘Best of market’, which is the category Tiziana will come into is a different matter and the worldwide market share to be gained here is off the scale.
Don’t forget, Remdesivir is the lead treatment at the moment and the US have stockpiled all supplies.
I’ve just got a gut feeling about Microsoft employee and investor Laura Fonda. She knows something...
https://www.google.com/amp/s/www.cbsnews.com/amp/news/pharmaceutical-companies-race-to-develop-monoclonal-antibody-treatment-for-covid-19/
https://www.google.com/amp/s/amp.cnn.com/cnn/2020/08/04/health/coronavirus-antibody-treatment-nih-trials-bn/index.html
Morning guys, I will post this again as it may have got lost amongst that drunken waffle last night. IMO it’s potentially an interesting connection .
Laura Fonda: 4.4% Ownership in Tiziana life sciences.
From LinkedIn: Senior Business Planner-Partner Incentives & ISV Strategy- Microsoft
Bill Gates gave an interview in the last couple of days telling how the single therapeutic he was most excited about was monoclonal antibodies.
Is this just a coincidental link?
Tiziana found it rather easy to raise $57million, almost with a click of the fingers.
Follow the money as they say....$$$$$
Laura Fonda knows something..
Maurice Silverman knows something..
The investor who just pumped in $57 million knows something..
Some of the criticism and conspiracy theories aimed at Bill Gates during this pandemic have been ludicrous.
He has held a long term interest in the subject and It would look great for him to be involved in the creation of a therapy for these diseases.
Laura Fonda: 4.4% Ownership in Tiziana life sciences.
From LinkedIn: Senior Business Planner-Partner Incentives & ISV Strategy- Microsoft
Bill Gates gave an interview in the last couple of days telling how the single therapeutic he was most excited about was monoclonal antibodies.
Is this just a coincidental link?
Tiziana found it rather easy to raise $57million, almost with a click of the fingers.